Novartis' Pluvicto is expected to dominate the market for radioligand therapies for prostate cancer, with ...
HANSIZHUANG (serplulimab) is the world's first anti-PD-1 mAb for first-line treatment of ES- SCLC - HANSIZHUANG (serplulimab) is expected to become the first and only anti-PD-1 ...
Researchers from the universities of Zurich, Yale and Harvard reveal the differences between the characteristics of the ...